BioSpace News Archive

Vor Bio, a clinical-stage cell and genome engineering company, announced that it will participate in the following upcoming investor conferences.

Champions Oncology, Inc. will report its financial and operational results for the first quarter ended July 31, 2022, on Thursday, September 8, 2022, after market close.

Evolus, Inc. announced that the Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 169,158 shares of Evolus common stock and 36,443 restricted stock units to Sandra Beaver, the company’s new Chief Financial Officer.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that Rick Pauls, its President and CEO will be participating at Lake Street Capital Market’s 6th Annual Best Ideas Growth (BIG6) Conference in New York, on September 14, 2022.

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced members of its management team will participate at the following investor conferences in September 2022.

Olema Pharmaceuticals, Inc. (“Olema,” “Olema Oncology” or the “Company,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that Shane Kovacs, Chief Operating and Financial Officer, will participate in a fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference.

Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that management will participate in investor meetings at the Citi 17th Annual BioPharma Conference on September 7 – 8, 2022 in Boston, Massachusetts.

Freeline Therapeutics Holdings plc announced that on August 31, 2022, the Company granted two newly hired employees non-statutory options to purchase an aggregate of 64,050 of the Company’s ordinary shares.

According to the current analysis of Reports and Data, the Pressure Ulcers Treatment market was valued at USD 5.36 billion in 2019 and is expected to reach USD 12.73 billion by the year 2027, at a CAGR of 11.4%.

The Laboratory Gas Generators Market was valued at USD 239.9 million in 2018 and is anticipated to reach USD 596.3 million in 2026 with a CAGR of 11.9%.